Met Life Investment Management, LLC Rallybio Corp Transaction History

Met Life Investment Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 09, 2024	BUY	$3.37 - $6.16 $57,219 - $104,590	16,979 New	16,979 $57,000
Q2 2023 Apr 29, 2024	BUY	$4.31 - $8.89 $73,179 - $150,943	16,979 New	16,979 $96,000
Q2 2023 Aug 10, 2023	BUY	$4.31 - $8.89 $73,179 - $150,943	16,979 New	16,979 $96,000
Q4 2022 Jun 14, 2023	BUY	$4.67 - $14.86 $48,002 - $152,745	10,279 New	10,279 $67,000
Q3 2022 May 10, 2024	BUY	$7.54 - $14.56 $77,503 - $149,662	10,279 New	10,279 $148,000
Q3 2022 Jun 14, 2023	BUY	$7.54 - $14.56 $77,503 - $149,662	10,279 New	10,279 $148,000
Q3 2022 Nov 14, 2022	BUY	$7.54 - $14.56 $77,503 - $149,662	10,279 New	10,279 $149,000

31.7M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $28M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.